Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients Authors: Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény Published: 2026 ABSTRACT AbstractIntroductionJanus kinase signal transducer and transcription activator (JAK–STAT) inhibitors have revolutionized the treatment of immune‐mediated inflammatory diseases (IMIDs) of the skin, such as in atopic dermatitis, alopecia areata and vitiligo. Although several meta‐analyses have confirmed their efficacy, concerns remain about the risk of infection, as the JAK–STAT pathway plays a key role in immune defence. Previous meta‐analyses examined only selected, pre‐specified infection categories and have not comprehensively evaluated all reported infection types or compared systemic and topical agents.MethodsWe performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) that reported infection‐related adverse events in patients treated with systemic or topical JAK–STAT inhibitors for IMIDs of the skin. The study followed the PRISMA 2020 and Cochrane guidelines (PROSPERO: CRD 42024615839). Overall risk ratios (RRs) with 95% confidence intervals (CI) were calculated using a random‐effects model.ResultsSeventy‐four RCTs were included, involving more than 29,000 patients. JAK–STAT inhibitors were associated with an increased risk of influenza (RR = 2.12, 95% CI 1.03–4.36), bronchitis (RR = 2.03, 95% CI 1.43–2.88) and herpes zoster (RR = 1.67, 95% CI 1.29–2.15) compared to a placebo. The risk was particularly elevated in patients with atopic dermatitis (influenza: 3.22, 95% CI 2.03–5.10, herpes zoster: RR = 2.00, 95% CI 1.34–2.99). No significant risks were identified for serious, fungal or opportunistic infections, and topical JAK–STAT inhibitors demonstrated a favourable safety profile comparable to vehicle controls.ConclusionsThis meta‐analysis provides a comprehensive assessment of the risk of infection associated with JAK–STAT inhibitors in IMIDs of the skin. Although overall safety is acceptable, clinicians should be aware of the higher infection risk of influenza and herpes zoster and should consider vaccination and preventive strategies for high‐risk patients with atopic dermatitis. The main limitation is that the included studies involved highly selected populations with few comorbidities and short follow‐up.Keywords: abrocitinib, adverse reactions, atopic dermatitis, baricitinib, brepocitinib, delgocitinib, deucravacitinib, deuruxolitinib, filgotinib, gusacitinib, herpes zoster, immune‐mediated inflammatory diseases of the skin, infection risk, influenza, itacitinib, ivarmacitinib, JAK–STAT inhibitor, Janus kinase inhibitors, peficitinib, povorcitinib, ritlecitinib, ropsacitinib, ruxolitinib, tofacitinib, upadacitinib, zasocitinib Why was the study undertaken? Evidence regarding the risk of infection associated with JAK–STAT inhibitors in immune‐mediated inflammatory skin diseases remains limited, as previous studies have not comprehensively assessed the wide range of infections. The present study addresses this gap, as the first meta‐analysis to evaluate more than 20 types of infections, including previously underreported conditions such as influenza, bronchitis and oral herpes. What does this study add? Atopic dermatitis showed the highest susceptibility, with JAK–STAT inhibitors significantly increasing the risk of influenza and herpes zoster compared to a placebo, and tripling the risk of herpes zoster compared to dupilumab. What are the implications of this study for disease understanding and/or clinical care? Despite these specific increases, no increased risk of serious, fungal or opportunistic infections was identified in the analysed RCTs, and topical JAK–STAT inhibitors demonstrated a favourable safety profile; however, these findings should be interpreted with caution, given the limitations of the included studies. INTRODUCTION Janus kinase signal transducer and transcription activator (JAK–STAT) inhibitors have revolutionized the treatment of immune‐mediated inflammatory skin diseases (IMIDs) of the skin such as atopic dermatitis, alopecia areata and vitiligo, 1 , 2 and their effectiveness has been confirmed by several meta‐analyses. 3 , 4 , 5 , 6 , 7 They provide a rapid and clinical improvement in multiple clinical domains of IMIDs of the skin by blocking multiple intracellular cytokine pathways that trigger inflammation and disease activity. 1 Despite their efficacy, safety concerns remain regarding the risk of infections associated with JAK–STAT inhibitors. The JAK–STAT pathway plays a crucial role in antiviral and antibacterial defence, and its inhibition may predispose patients to infections. 8 A recent pharmacovigilance analysis based on the FDA Adverse Event Reporting System suggests an overall increased risk of infection with several JAK inhibitors, including herpes zoster, influenza and COVID‐19. 9 Previous meta‐analyses in dermatology indications have mainly focused on only pre‐specified infection types, such as upper respiratory infection, nasopharyngitis, serious infection and folliculitis, 10 , 11 , 12 , 13 and no analysis has comprehensively evaluated all types of reported infections separately in skin diseases. Furthermore, previous studies have not systematically compared JAK–STAT inhibitors with active comparators and have not specifically evaluated topical JAK–STAT inhibitors. To date, no meta‐analysis has provided such an integrated and in‐depth assessment of the risk of infection in this therapeutic class. Therefore, our study aimed to conduct the first comprehensive systematic review and meta‐analysis of randomized controlled trials (RCTs) evaluating the infection risks associated with systemic and topical JAK–STAT inhibitors in IMIDs of the skin. METHODS This study was conducted as part of the System Education Program at Semmelweis University 14 and within the Translational Medicine TM Cycle Framework of Academia Europaea. 15 This systematic review and meta‐analysis was performed in accordance with the instructions in the Cochrane Handbook 16 and reported following PRISMA 2020 guidelines. 17 The protocol was prospectively registered with PROSPERO (CRD42024615839). Eligibility criteria This study included only RCTs that compared a systemic or topical JAK–STATi with a placebo and/or an active comparator (non‐JAK–STATi), and investigated the safety and reported infection‐related adverse events in patients with alopecia, psoriasis, vitiligo, atopic dermatitis or hidradenitis suppurativa. We did not apply any restriction based on the type of infection to ensure a comprehensive assessment of infection risk. Pooled analyses and post hoc analyses of RCTs were excluded, and the original study was included. The trials were included in the synthesis only up to the time point of treatment change or crossover, and only if the available outcome data were still comparable with the initial placebo or active‐comparator group. Search strategy and selection process The systematic search was conducted in three databases (MEDLINE via PubMed, EMBASE and Cochrane Library) on 19 November 2024. No special filters, settings or restrictions were made. The detailed search strategy is presented in the Supporting Information Material, including the number of hits in each database. Upon completing the systematic search, the retrieved articles were imported into EndNote (version 21, Clarivate Analytics, Philadelphia, PA, USA). 18 Duplicates were automatically and manually removed within EndNote. The selection process was performed independently by two reviewers (M.K. and M.V.K.), first by reviewing the titles and abstracts and then by assessing the full text using Rayyan Systems software (Cambridge, MA, USA). 19 A third reviewer (L.G.) resolved disagreements. Data collection and synthesis A standardized data collection sheet based on a consensus of methodological and clinical experts was used to extract the data. Two independent reviewers (M.K. and B.N.) extracted the following data from eligible articles: first author's last name, publication year, disease, number of patients, study duration, population characteristics, intervention, comparators, type of adverse event and number of adverse events. Infectious adverse events were not pre‐specified and not restricted by type. This meta‐analysis included all infection‐related outcomes that were reported in at least three RCTs. These outcomes were: upper respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, influenza, bronchitis, COVID‐19, pneumonia, oral herpes, herpes zoster, herpes simplex, genital herpes, eczema herpeticum, urinary tract infection, folliculitis, gastroenteritis, wound infection, opportunistic infection, serious infection, candida and tinea infection. Serious infections were analysed as reported in the RCTs. Across studies, these definitions were broadly consistent with standard criteria for serious adverse events, including infections that result in death, life‐threatening conditions or hospitalization or parenteral antimicrobial treatment. However, minor variations in definitions and reporting may have been present across individual studies. We evaluated the risk of bias using the Risk of Bias Tool 2 (RoB 2). 20 It was conducted by two independent reviewers (M.K. and B.N.), and any disagreements were resolved by a third independent reviewer (L.G.). Publication bias was assessed by visual inspection of the funnel plots. The quality of evidence was evaluated using the GRADE‐Pro tool as recommended by the Cochrane Collaboration. 21 Statistical analysis As we assumed considerable between‐study heterogeneity in all cases, a random‐effects model was used to pool effect sizes. In the case of dichotomous outcomes, the risk ratio (RR) with 95% confidence interval (CI) was used for the effect size measure. To calculate the study risk ratios and the pooled risk ratio, the total number of patients and those with the event of interest in each group separately (referred to as ‘raw data’) were extracted or calculated from the studies where available. We reported the results as the risk of the event of interest in the experimental group versus the risk of the event of interest in the control group. Results were considered statistically significant if the pooled CI did not contain the null value. We summarized the findings related to the meta‐analysis on forest plots. Absolute between‐study heterogeneity was expressed by tau, and relative between‐study heterogeneity was described by Higgins and Thompson's I 2 statistics. 22 Where applicable and the study number was large enough and not too heterogeneous, we reported the prediction intervals (i.e., the expected range of true effects of future studies) of results too. All analyses were performed in R. 23 Further details are provided in the Supporting Information Material. RESULTS Search and selection The systematic search yielded a total of 5065 records. After selecting the title, abstract and full text, 69 articles met the inclusion criteria. No additional study was identified by citation search. A total of 69 articles, 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 including the results of 74 RCTs, were included in the systematic review and meta‐analysis. The selection process is detailed in Figure 1. A total of 68 RCTs 24 , 25 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 88 , 89 , 90 , 91 , 92 , 93 were eligible for quantitative synthesis. One RCT 75 was included only in the qualitative analysis. Five multi‐arm RCTs 27 , 49 , 50 , 65 , 87 were analysed in both quantitative and qualitative synthesis, as some active comparator arms (apremilast, zimlovisertib, tacrolimus, triamcinolone) were not suitable for quantitative analysis due to an insufficient number of identical comparators. PRISMA 2020 flow chart representing the study selection process. Basic characteristics of included studies Baseline characteristics of the included RCTs are detailed in Table S1. Quantitative analysis A comprehensive overview of all findings is provided in Table 1 and Tables S2–S6. Significant results have been highlighted separately in Table 1. All outcomes in each table are sorted in descending order based on the pooled risk ratio (RR), which reflects the correlation between the intervention and each endpoint. TABLE 1Summary of statistically significant results.OutcomesNumber of results (n)JAK‐STATi events (n)JAK‐STATi Total (n)Prevalence on JAK‐STATi (%)Placebo events (n)Placebo total (n)Prevalence on placebo (%)Relative risk95% confidence intervalOral herpes117841791.87713640.512.751.93–3.92Influenza119037462.401312621.032.121.03–4.36Bronchitis116631342.1179040.772.031.43–2.88Herpes zoster42149130721.141748320.351.671.29–2.15Pharyngitis72716961.59550011.441.06–1.96Upper respiratory tract infection51957151666.3129158704.961.251.12–1.39Abbreviations: JAK‐STATi, Janus kinase–signal transducer and activation of transcription inhibitor; n = number. Summary of statistically significant results. Abbreviations: JAK‐STATi, Janus kinase–signal transducer and activation of transcription inhibitor; n = number. To our knowledge, this is the first meta‐analysis to investigate the prevalence of influenza in patients treated with JAK–STAT inhibitors in IMIDs of the skin, revealing a significantly increased risk compared to the placebo group. Influenza was assessed in 11 studies, involving 3746 people exposed to JAK–STATi and 1262 people exposed to a placebo. JAK–STAT inhibitors were associated with a significantly higher risk of influenza compared with a placebo (RR = 2.12, 95% CI 1.03–4.36) (Figure 2). Upon subgroup analysis based on diseases, we identified that risk increases dominantly in patients with atopic dermatitis with a risk ratio of 3.22 (95% CI, 2.03–5.10) (see Figure S1). Risk of influenza associated with JAK‐STAT inhibitor treatment compared with placebo. RR, risk ratio; JAK‐STATi, Janus kinase–signal transducer and activation of transcription inhibitor; CI, confidence interval. We observed that other respiratory infections also showed a significantly increased risk in the JAK–STATi group. Bronchitis was assessed in 11 studies, including 3134 patients receiving JAK–STAT inhibitors and 904 patients receiving a placebo, and was associated with a significantly increased risk compared with a placebo (RR = 2.03, 95% CI 1.43–2.88) (see Figure S2). Similarly, pharyngitis, assessed in 7 trials, occurred more often among patients receiving JAK–STAT inhibitors than a placebo (RR = 1.44, 95% CI 1.06–1.96) (see Figure S3). We also observed a significant increase in upper respiratory tract infections among patients treated with JAK–STATi compared with a placebo (RR = 1.25, 95% CI 1.12–1.39) (see Figure S4). Subgroup analysis based on diseases showed a significantly higher risk ratio for patients with atopic dermatitis (RR = 1.26, 95% CI 1.08–1.47) and for patients with psoriasis (RR = 1.62, 95% CI 1.21–2.17) (see Figure S5). There was no significant increased risk with JAK–STAT inhibitors for nasopharyngitis (RR = 1.08, 95% CI 0.97–1.20), sinusitis (RR = 1.14, 95% CI 0.71–1.82), COVID‐19 (RR = 1.09, 95% CI 0.78–1.52) or pneumonia (RR = 0.46, 95% CI 0.07–3.14) (see Figures S6–S9). Among herpetic infections, oral herpes showed the highest relative risk compared with a placebo (RR = 2.75, 95% CI 1.93–3.92) (see Figure S10). Subgroup analysis showed that the risk ratio was particularly high in patients with atopic dermatitis (RR = 3.29, 95% CI 2.30–4.71) (see Figure S11). This outcome was reported as oral herpes without further specification of the clinical subtype. Herpes zoster was assessed in 42 studies, including 13,072 patients receiving JAK–STAT inhibitors and 4832 patients receiving a placebo. The risk of herpes zoster was significantly higher among patients exposed to JAK–STAT inhibitors (RR = 1.67, 95% CI 1.29–2.15) (Figure 3). Subgroup analysis based on diseases demonstrated a significantly higher risk ratio for herpes zoster in patients with atopic dermatitis compared with a placebo (RR = 2.00, 95% CI 1.34–2.99) (see Figure S12), and this risk increased further compared with the dupilumab in atopic patients (RR = 3.52, 95% CI 1.82–6.81) (see Figure S13). Furthermore, a significantly increased risk was observed in patients with psoriatic arthritis (RR = 1.79, 95% CI 1.17–2.75) (see Figure S12). Risk of herpes zoster associated with JAK‐STAT inhibitor treatment compared with placebo. RR, risk ratio; JAK‐STATi, Janus kinase–signal transducer and activation of transcription inhibitor; CI, confidence interval. Neither herpes simplex, genital herpes nor eczema herpeticum infections showed a significant association with the use of JAK–STAT inhibitors (RR = 1.04, 95% CI 0.70–1.55; RR = 0.95, 95% CI 0.27–3.31; RR = 0.64, 95% CI 0.32–1.29, respectively) (see Figures S14–S16). There were no significant differences between the JAK–STAT and placebo groups for other infection types in patients treated with JAK–STATi, including gastroenteritis (RR = 1.14, 95% CI 0.52–2.50), folliculitis (RR = 1.05, 95% CI 0.56–1.98), urinary tract infection (RR = 1.02, 95% CI 0.81–1.28) and opportunistic infection (RR = 0.70, 95% CI 0.48–1.03) (see Figures S17–S20). No significant increased risk was observed for fungal infections in patients treated with JAK–STATi, including candida infection (RR = 0.94, 95% CI 0.27–3.27) and tinea infection (RR = 0.56, 95% CI 0.21–1.46) (see Figures S21 and S22). Serious infections were assessed in 34 studies, including 11,040 patients receiving JAK–STAT inhibitors and 4338 patients receiving a placebo. No statistically significant difference in the risk of serious infection was observed between the two groups (RR = 1.09, 95% CI 0.80–1.47) (see Figure S23). No significant differences in the risk of infections were observed between JAK–STAT inhibitors and dupilumab or TNF inhibitors, except for the previously mentioned increased risk of herpes zoster in patients with atopic dermatitis compared with dupilumab (see Tables S3 and S4, Figures S24–S31). Topical JAK–STAT inhibitors did not show a significantly increased risk of infection compared to a vehicle (see Table S5, Figures S32–S37). Qualitative analysis The results of the studies not suitable for statistical synthesis are summarized in Table S6. These included studies comparing JAK–STAT inhibitors with active comparators, such as apremilast, azathioprine and zimlovisertib. No significant differences in the risk of infections were observed in the trials except for one (Armstrong et al. 27 ) wheren upper respiratory tract infections were significantly increased in the JAK–STAT group compared with apremilast (RR = 3.54, 95% CI 1.07–11.71). In addition, topical JAK–STAT inhibitors using active comparators such as tacrolimus and triamcinolone were analysed qualitatively. No significant differences in the risk of infection were observed. Risk of bias assessment When assessing the risk of bias, the majority of RCTs were classified as low risk, some were classified as medium risk and none were classified as high risk. A detailed risk of bias assessment can be found in the Tables S7 and S8. Publication bias The funnel plots for our outcomes did not show evidence of publication bias (see Figures S38–S72). Certainty of evidence The certainty assessment is described in Tables S9–S12. DISCUSSION To our knowledge, this meta‐analysis is the most comprehensive study to evaluate the risk of infections associated with JAK–STAT inhibitors in IMIDs of the skin, analysing more than 20 types of infections. In addition to confirming previously known infection risks, it also provides new insights by identifying and quantifying the risk of specific infections, such as influenza, which have not been systematically evaluated in previous studies. Another novelty is that we examined the risk of infection not only in comparison with placebos but also in comparison with other active comparators. Atopic dermatitis is itself highly susceptible to skin infection and systemic infection like respiratory viral infections, possibly due to underlying immune dysregulations and defects in the skin barrier. 94 , 95 , 96 The use of JAK–STAT inhibitors in atopic dermatitis may further impair the antiviral immune response, as JAK–STAT signalling is critical for interferon‐mediated antiviral protection. 97 , 98 As the JAK–STAT pathway plays a central role in antiviral defence, its inhibition may also contribute to the increased susceptibility to herpes zoster observed in patients receiving these agents. 99 Consistent with this mechanism, this is the first meta‐analysis to show an increased risk of influenza in patients treated with JAK–STAT inhibitors compared to placebos in IMIDs of the skin. This is particularly relevant for elderly patients, who are already more susceptible to influenza infection and are at greater risk of developing serious complications. 100 , 101 Advanced age is a well‐known risk factor for infection, which is partly attributable to the aging of the immune system, which impairs the functioning of both the innate and adaptive immune responses. 102 , 103 , 104 In addition, a higher burden of comorbidities and concurrent treatments further increase older adults' susceptibility to infection. 105 , 106 , 107 The use of JAK–STAT inhibitors in elderly patients with atopic eczema should be carefully considered, weighing the benefits of disease control against the increased risk of influenza and the potential serious complications. Consideration of annual influenza vaccination and close surveillance is recommended for this high‐risk group. 108 Our analysis did not confirm a significant risk of COVID‐19 infection among patients treated with JAK–STAT inhibitors, but this result should be interpreted with caution. JAK–STAT inhibitors have been investigated as therapeutic agents in severe COVID‐19 cases to alleviate cytokine‐induced hyperinflammation. 109 , 110 While such immunomodulatory effects may be beneficial in acute cytokine storms, these agents may continue to influence antiviral defence mechanisms during chronic treatment of inflammatory diseases. Real‐world data are needed to clarify the long‐term relationship between JAK–STAT inhibition and COVID‐19 susceptibility. Recent meta‐analyses and large cohort studies have consistently shown that JAK–STAT inhibitors are associated with an increased risk of respiratory tract infections in dermatological indications. 10 , 12 Specifically, upper respiratory infections and pharyngitis were common adverse events in patients receiving JAK inhibitors, with similar risk ratios to those found in our analysis. These infections are typically mild to moderate in severity and rarely lead to treatment interruption or serious side effects. The specific infectious agents responsible for these respiratory infections were not reported in the included studies; therefore, pathogen‐specific analysis was not feasible. Our meta‐analysis is the first to show a significantly increased risk of bronchitis associated with JAK–STAT inhibitor treatment. This new finding expands the current knowledge of respiratory adverse events associated with JAK–STAT inhibition. Although most bronchitis cases were mild, this observation emphasizes the importance of clinical vigilance, especially in patients with pre‐existing lung disease or those receiving concomitant immunosuppressive therapy. 111 The identification of a previously unreported increased risk of oral herpes among patients treated with JAK–STAT inhibitors is significant because it adds to the current knowledge of JAK–STAT‐related viral susceptibility and class‐specific safety concerns in dermatological indications. Previous meta‐analyses have focused on herpes zoster and broader infection risks but have not quantified oral herpes as an outcome. 10 , 12 , 112 This finding highlights the importance of patient education regarding possible herpetic infections, particularly in patients with atopic dermatitis with an elevated basal infection risk. It supports the need for individualized risk assessment and preventive strategies, as recommended by the American Academy of Allergy, Asthma and Immunology. 113 Meta‐analyses and large cohort studies have shown that JAK–STAT inhibitors are associated with an increased risk of herpes zoster compared to placebos and dupilumab. 10 , 12 , 112 , 114 Our results are consistent with these observations. They should also be interpreted in the context of recent real‐world and long‐term safety observations. In the prospective BioDay registry, patients with moderate‐to‐severe atopic dermatitis who received JAK inhibitors had higher infection rates than those on biologics, especially herpes infections. 115 In addition, a 6‐year safety analysis of upadacitinib for the treatment of atopic dermatitis showed that the incidence of infections varied significantly by dose. 116 At the 30 mg dose, there was an increased incidence of herpes zoster, as well as a slight increase in the number of serious and opportunistic infections. These safety data further reinforce the clinical importance of stratifying infection risk within the JAK inhibitor class. Together, our findings and these data further reinforce the importance of herpes zoster vaccination prior to initiating JAK–STAT inhibitor therapy, in line with American Academy of Dermatology guidelines, particularly in adults aged 50 years or older and in immunocompromised patients with atopic dermatitis, 117 and supported by European recommendations, including a position statement of the Italian Society of Dermatology and Venereology. 118 In high‐risk populations, dupilumab should be considered as an alternative treatment option for atopic dermatitis, given its more favourable herpetic viral infection profile. A previous meta‐analysis of 19 RCTs in dermatologic indications reported modest increases in folliculitis (RR = 1.68, 95% CI 1.03–2.77) and nasopharyngitis (RR = 1.36, 95% CI 1.15–1.61). 13 We observed similar trends, but these were not significant in our analysis. Although JAK–STAT inhibitors can affect immune cells involved in antifungal defence, including Th1, Th17 and phagocyte activation, leading to a decrease in neutrophil activation and cytokine production, 119 a previous report has suggested a possible association with fungal infections. 96 However, our meta‐analysis did not find a significant increase in candida or tinea infection risk among patients receiving JAK‐STAT inhibitors. The phase III ORAL clinical study found that patients treated with JAK inhibitors for rheumatoid arthritis may have a higher risk of serious infections. 120 In contrast, our analysis found no significant risk of serious infection compared to a placebo, in line with previous meta‐analysis. 10 , 11 , 12 Compared to previous meta‐analyses, our analysis also included studies with active comparators, such as dupilumab and TNF inhibitors, and similarly found no significant difference in the risk of serious infection between JAK–STAT inhibitors and active comparators. The ORAL study included patients aged 50 years or older with rheumatoid arthritis who had at least one additional cardiovascular risk factor, representing a higher risk population than those enrolled in dermatology clinical trials. Compared to the ORAL study, the patients included in our meta‐analysis were generally younger, had fewer comorbidities and some of the RCTs included children. These demographic differences, as well as the lack of concomitant methotrexate use, may contribute to the lower incidence of serious infections in our analysis. In addition, the median follow‐up period for ORAL was approximately 4 years. In contrast, the treatment periods in most included dermatological studies were short, and only a few studies lasted 52 weeks. Consistent with a previous pharmacokinetic study, topical JAK‐STAT inhibitors did not increase the risk of infection compared to a vehicle, supporting a favourable systemic infection safety profile with the use recommended in the guidelines. 121 , 122 Strengths This study has several important strengths. To our knowledge, it is the most comprehensive meta‐analysis to date evaluating the risk of JAK‐STAT‐related infections in IMIDs of the skin, assessing more than 20 different types of infections. The analysis integrates evidence from placebo‐controlled and active comparative trials—including dupilumab and TNF inhibitors—and distinguishes between systemic and topical therapies. Furthermore, by synthesizing data from 74 RCTs involving more than 29,000 patients, this study provides the most statistically robust safety assessment available and identifies previously unreported infection types, such as increased risk of influenza, bronchitis and oral herpes, while confirming no increased risk of serious fungal or opportunistic infections. Limitations This study has several limitations. The majority of RCTs included had a short median follow‐up period, and only a few extended over a longer period. Therefore, our results mainly reflect short‐term safety outcomes, and long‐term infectious risks remain uncertain. In addition, the study populations were highly selected, consisting predominantly of middle‐aged patients with few comorbidities, which may limit the generalizability of our results to real‐world or elderly populations. Furthermore, although infection results were consistently reported, definitions and diagnostic criteria may not have been entirely consistent across studies. The assessment of some infections may have been investigator‐dependent. Furthermore, diagnostic methods were not always consistent across studies, with some studies relying solely on clinical presentation, while others used specific tests for confirmation. In addition, the classification of certain infections was limited by the original reporting of the included RCTs; for example, ‘oral herpes’ was not further specified, which may affect the precision of outcome definitions. Implication for practice and research Although the prevalence of infections was low, this likely reflects the short follow‐up period. Even a modest increase in the risk of infection may have important clinical consequences in real‐life settings, where patients often receive long‐term therapy and may have additional risk factors, such as advanced age, comorbidities or concomitant immunosuppressive treatment. Integrating evidence into clinical practice is a core principle of the Academia Europaea Translational Medicine framework. 123 , 124 Our findings highlight the importance of patient education, as well as assessing and preventing the risk of infection, prior to initiating JAK–STAT inhibitor therapy, particularly in patients with atopic dermatitis. Vaccination against influenza and herpes zoster should be considered before initiating treatment in high‐risk populations, as should annual re‐evaluation. In high‐risk atopic populations, such as the elderly or immunocompromised patients, dupilumab may be a safer alternative due to its lower herpes infection risk profile. Further large‐scale, real‐world, long‐term studies are needed to clarify the long‐term infection risk profile of JAK–STAT inhibitors outside controlled trial settings. CONCLUSIONS This meta‐analysis supports the safe use of JAK‐STAT inhibitors in dermatological indications. However, clinicians should be aware of a modest increase in infection risk, especially in patients with atopic dermatitis. These findings suggest that herpes zoster and influenza vaccination should be considered before starting the treatment in a high‐risk population. AUTHOR CONTRIBUTIONS Máté Krebs: Conceptualization, project administration, methodology, formal analysis and writing—original draft. Lili Gulyás: Conceptualization, formal analysis, visualization, writing—review and editing. Karen Krisztina Fazekas: Methodology, formal analysis, validation, visualization and writing—review and editing. Benedek Nagy: Data curation and writing—review and editing. Mária Veronika Kolonics: Conceptualization, data curation and writing—review and editing. Fanni Adél Meznerics: Conceptualization, methodology, supervision and writing—review and editing. Norbert Kiss: Conceptualization, methodology, supervision and writing—review and editing. András Bánvölgyi: Conceptualization, methodology, supervision and writing—review and editing. Péter Hegyi.: Conceptualization, methodology, supervision and writing—review and editing. Péter Holló: Conceptualization, methodology, supervision and writing—original draft. Lajos Vince Kemény: Conceptualization, methodology, supervision and writing—original draft. All authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing or revision of the manuscript. FUNDING INFORMATION The authors have nothing to report. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICAL APPROVAL No ethical approval was required for this systematic review with meta‐analysis, as all data were already published in peer‐reviewed journals. ETHICS STATEMENT No patients were involved in the design, conducting or interpretation of our study. Supporting information Figures S1–S72. Tables S1–S13. Data S2. Krebs M, Gulyás L, Fazekas KK, Nagy B, Kolonics MV, Meznerics FA, et al. Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients. J Eur Acad Dermatol Venereol. 2026;40:1662–1674. 10.1111/jdv.70508 Péter Holló and Lajos Vince Kemény share last authorship. Contributor Information Péter Holló, Email: hollo.peter@semmelweis.hu. Lajos Vince Kemény, Email: kemeny.lajos@semmelweis.hu. DATA AVAILABILITY STATEMENT The datasets used in this study can be found in the full‐text articles included in the systematic review and meta‐analysis. REFERENCES Associated Data Supplementary Materials Figures S1–S72. Tables S1–S13. Data S2. Data Availability Statement The datasets used in this study can be found in the full‐text articles included in the systematic review and meta‐analysis.